![]() |
|
|
SL Walsh, JT Sullivan, KL Preston, JE Garner and GE Bigelow
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
This study evaluated the effects of i.v. cocaine, hydromorphone and their combination, and assessed the ability of oral naltrexone, an opioid antagonist, to modulate these effects. Volunteers with cocaine and heroin abuse histories (n = 8) participated in this placebo- controlled, cross-over study while residing on a closed research unit. Daily treatment with capsules containing placebo or naltrexone in ascending doses (3.125, 12.5, 50 and 200 mg) were given for 7-day periods. In thrice weekly experimental sessions, cocaine, hydromorphone and their combination were given in random order. Drug doses were given in an ascending order 1 hr apart as follows: cocaine at 0,20 and 40 mg, hydromorphone at 0, 1.5 and 3.0 mg, and the combination of 0 and 0 mg, 20 mg cocaine and 1.5 mg hydromorphone and 40 mg cocaine and 3.0 mg hydromorphone. Hydromorphone and cocaine produced distinct pharmacodynamic profiles, and the combination produced effects similar to both drugs. In some cases, the magnitude of effects produced by the combination was greater than that produced by either drug alone. Naltrexone produced dose-related blockade of hydromorphone effects, but did not after any of the physiological or subjective effects of cocaine. All naltrexone doses partially attenuated the effects of the combination and this appeared to be attributable to selective opioid blockade. These data do not support the use of naltrexone as a treatment for cocaine abuse, but suggest it may be useful for treating patients with concurrent cocaine and heroin abuse.
This article has been cited by other articles:
![]() |
M. C. H. Ko, M. F. Divin, H. Lee, J. H. Woods, and J. R. Traynor Differential in Vivo Potencies of Naltrexone and 6beta-Naltrexol in the Monkey J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 772 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. McMahon, S. L. Sell, and C. P. France Cocaine and Other Indirect-Acting Monoamine Agonists Differentially Attenuate a Naltrexone Discriminative Stimulus in Morphine-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 111 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260. [Abstract] [PDF] |
||||
![]() |
E. C Strain Review: there is insufficient evidence for naltrexone maintenance treatment in opioid dependence Evid. Based Ment. Health, May 1, 2003; 6(2): 57 - 57. [Full Text] [PDF] |
||||
![]() |
D. M. Platt, D. M. Grech, J. K. Rowlett, and R. D. Spealman Discriminative Stimulus Effects of Morphine in Squirrel Monkeys: Stimulants, Opioids, and Stimulant-Opioid Combinations J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1092 - 1100. [Abstract] [Full Text] |
||||
![]() |
J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Rowlett, K. M. Wilcox, and W. L. Woolverton Self-Administration of Cocaine-Heroin Combinations by Rhesus Monkeys: Antagonism by Naltrexone J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 61 - 69. [Abstract] [Full Text] |
||||
![]() |
S. S. Negus, M. B. Gatch, and N. K. Mello Discriminative Stimulus Effects of a Cocaine/Heroin "Speedball" Combination in Rhesus Monkeys J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1123 - 1136. [Abstract] [Full Text] |
||||
![]() |
N. K. Mello and S. S. Negus The Effects of Buprenorphine on Self-administration of Cocaine and Heroin "Speedball" Combinations and Heroin Alone by Rhesus Monkeys J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 444 - 456. [Abstract] [Full Text] |
||||